Guggenheim Capital LLC Immuno Gen, Inc. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $74,535 - $179,160	-5,982 Reduced 6.58%	84,991 $2.52 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $1.28 Million - $1.81 Million	90,973 New	90,973 $1.44 Million
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $964,697 - $2.38 Million	-244,847 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $181,520 - $237,664	21,107 Added 9.43%	244,847 $2.32 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $171,531 - $218,918	18,018 Added 8.76%	223,740 $2.18 Million
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $423,218 - $818,012	-63,167 Reduced 23.49%	205,722 $2.16 Million
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $1.36 Million - $2.13 Million	268,889	268,889 $1.72 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.